Urotensin II levels in patients with chronic kidney disease and kidney transplants

References

• McDonald J, Batuwangala M, Lambert DG. Role of urotensin II and its receptor in health and disease. J Anesth. 2007;21:378–89.
   PubMed Web of Science ®Google Scholar
• Zhu YC, Zhu YZ, Moore PK. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol. 2006;148:884–901.
   PubMed Web of Science ®Google Scholar
• Ng LL, Loke I, O’Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation. 2002;106:2877–80.
   PubMed Web of Science ®Google Scholar
• Tian L, Li C, Qi J, Fu P, Yu X, Li X, Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction. Am J Physiol Endocrinol Metab. 2008;295:E1234–42.
   Google Scholar
• Abdel-Razik AE, Forty EJ, Balment RJ, Ashton N. Renal haemodynamic and tubular actions of urotensin II in the rat. J Endocrinol. 2008;198:617–24.
   PubMedGoogle Scholar
• Mosenkis A, Danoff TM, Aiyar N, Bazeley J, Townsend RR. Human urotensin II in the plasma of anephric subjects. Nephrol Dial Transplant. 2007;22:1269–70.
   PubMedGoogle Scholar
• Zoccali C, Mallamaci F. Urotensin II: a cardiovascular and renal update. Curr Opin Nephrol Hypertens. 2008;17:199–204.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Hirose T, Mori N, Morimoto R, Kohzuki M, Imai Y, The renin-angiotensin system, adrenomedullins and urotensin II in the kidney: possible renoprotection via the kidney peptide systems. Peptides. 2009;30:1575–85.
   PubMed Web of Science ®Google Scholar
• Ashton N. Renal and vascular actions of urotensin II. Kidney Int. 2006;70:624–9.
   PubMed Web of Science ®Google Scholar
• Ong KL, Wong LY, Cheung BM. The role of urotensin II in the metabolic syndrome. Peptides. 2008;29:859–67.
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guideline for the care of kidney transplant recipients. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. Am J Transplant. 2009;9(Suppl 3):S1–155.
   PubMed Web of Science ®Google Scholar
• Gill JS, Rose C, Pereira BJ, Tonelli M. The importance of transitions between dialysis and transplantation in the care of end-stage renal disease patients. Kidney Int. 2007;71:442–7.
   PubMedGoogle Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Lapp H, Boerrigter G, Costello-Boerrigter LC, Jaekel K, Scheffold T, Krakau I, Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol. 2004;94:93–7.
   PubMed Web of Science ®Google Scholar
• Kobori H, Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens. 2008;2:349–54.
   PubMed Web of Science ®Google Scholar
• Mosenkis A, Kallem RR, Danoff TM, Aiyar N, Bazeley J, Townsend RR. Renal impairment, hypertension and plasma urotensin II. Nephrol Dial Transplant. 2011;26:609–14.
   PubMed Web of Science ®Google Scholar
• Mori N, Hirose T, Nakayama T, Ito O, Kanazawa M, Imai Y, Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure. Peptides. 2009;30:400–8.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Arita S, Shiraishi Y, Suguro T, Sakai T, Hongo S, Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. Curr Med Chem. 2009;16:550–63.
   PubMedGoogle Scholar
• Zomer E, de Ridder I, Kompa A, Komesaroff P, Gilbert R, Krum H. Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension. Clin Exp Pharmacol Physiol. 2008;35:1147–50.
   PubMed Web of Science ®Google Scholar
• Gaillard T, Schuster D, Osei K. Metabolic syndrome in Black people of the African diaspora: the paradox of current classification, definition and criteria. Ethn Dis. 2009;19(Suppl 2): S2–1–7.
   PubMedGoogle Scholar
• Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol. 2007;293:F2–9.
   PubMed Web of Science ®Google Scholar
• Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol. 2000;35(Suppl 1):S7–11.
   PubMedGoogle Scholar
• Reis FN. The unsolved cyclosporine-induced kidney injury: is paricalcitol a feasible new renoprotective option? Kidney Int. 2010;77:1055–7.
   PubMedGoogle Scholar
• Carvalho da Costa M, De Castro I, Neto AL, Ferreira AT, Burdmann EA, Yu L. Cyclosporine A tubular effects contribute to nephrotoxicity: role for Ca2+ and Mg2+ ions. Nephrol Dial Transplant. 2003;18:2262–8.
   PubMedGoogle Scholar
• Rossowski WJ, Cheng BL, Taylor JE, Datta R, Coy DH. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol. 2002;438:159–70.
   PubMed Web of Science ®Google Scholar
• Vereerstraeten P, Wissing M, De Pauw L, Abramowicz D, Kinnaert P. Male recipients of kidneys from female donors are at increased risk of graft loss from both rejection and technical failure. Clin Transplant. 1999;13:181–6.
   PubMedGoogle Scholar
• Hutchens MP, Dunlap J, Hurn PD, Jarnberg PO. Renal ischemia: does sex matter? Anesth Analg. 2008;107:239–49.
   PubMed Web of Science ®Google Scholar